{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:14:19Z","timestamp":1791342859453,"version":"4.3.1"},"reference-count":76,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2000,11,1]],"date-time":"2000-11-01T00:00:00Z","timestamp":973036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2000,11]]},"DOI":"10.1136\/ard.59.11.841","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:45:32Z","timestamp":1027766732000},"page":"841-849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":390,"title":["Leflunomide: mode of action in the treatment of rheumatoid arthritis"],"prefix":"10.1016","volume":"59","author":[{"given":"F C","family":"Breedveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-M","family":"Dayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard.59.11.841_bib1","first-page":"3","article-title":"New insights in the pathogenesis of rheumatoid arthritis.","volume":"53(suppl)","author":"Breedveld","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.59.11.841_bib2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.1780380202","article-title":"Inhibition of the production and effects of interleukin-1 and tumor necrosis factor-\u00ce\u00b1 in rheumatoid arthritis.","volume":"38","author":"Arend","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.11.841_bib3","series-title":"T cells in arthritis.","first-page":"111","article-title":"Interactions between T cell plasma membranes and monocytes.","author":"Burger","year":"1998"},{"key":"10.1136\/ard.59.11.841_bib4","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0952-7915(96)80090-2","article-title":"Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide.","volume":"8","author":"Brazleton","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"10.1136\/ard.59.11.841_bib5","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1517\/13543784.6.1.51","article-title":"Leflunomide and malononitriloamides.","volume":"6","author":"Silva","year":"1997","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"10.1136\/ard.59.11.841_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF01778336","article-title":"Leflunomide, a reversible inhibitor of pyrimidine biosynthesis.","volume":"44(suppl 2)","author":"Zielinski","year":"1995","journal-title":"Inflamm Res"},{"key":"10.1136\/ard.59.11.841_bib7","first-page":"1043","article-title":"The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis.","volume":"275","author":"Cherwinski","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1136\/ard.59.11.841_bib8","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/BF01796261","article-title":"Leflunomide interferes with pyrimidine nucleotide biosynthesis.","volume":"44","author":"Cherwinski","year":"1995","journal-title":"Inflamm Res"},{"key":"10.1136\/ard.59.11.841_bib9","first-page":"1016","article-title":"Mechanism of the anti-proliferative action of leflunomide.","volume":"14","author":"Cao","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"10.1136\/ard.59.11.841_bib10","doi-asserted-by":"crossref","first-page":"22467","DOI":"10.1074\/jbc.270.38.22467","article-title":"Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound.","volume":"270","author":"Williamson","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.59.11.841_bib11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0006-2952(96)00303-6","article-title":"Two activities of the immunosuppresive metabolite of leflunomide, A77 1726: inhibition of pyrimidine nucleotide synthesis and protein tyrosine phosphorylation.","volume":"52","author":"Xu","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1136\/ard.59.11.841_bib12","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00007890-199601150-00026","article-title":"Effects of leflunomide and other immunosuppressive agents on T cell proliferation in vitro.","volume":"61","author":"Chong","year":"1996","journal-title":"Transplantation"},{"key":"10.1136\/ard.59.11.841_bib13","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1097\/00007890-199602270-00020","article-title":"Regulation of B cell function by the immunsuppressive agent leflunomide.","volume":"61","author":"Siemasko","year":"1996","journal-title":"Transplantation"},{"key":"10.1136\/ard.59.11.841_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4049\/jimmunol.159.1.22","article-title":"The immunosuppressive metabolite of leflunomide, A77 1726, affects murine T cells through two biochemical mechanisms.","volume":"159","author":"Elder","year":"1997","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.11.841_bib15","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.4049\/jimmunol.160.4.1581","article-title":"Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production.","volume":"160","author":"Siemasko","year":"1998","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.11.841_bib16","first-page":"3088","article-title":"Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide.","volume":"28","author":"Spinella-Jaegle","year":"1996","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib17","first-page":"3082","article-title":"Mechanism of action of leflunomide: in vivo uridine administration reverses its inhibition of lymphocyte proliferation.","volume":"28","author":"Silva","year":"1996","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib18","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1039\/p19920002203","article-title":"Novel immunosuppressive butenamides.","volume":"1","author":"Axton","year":"1992","journal-title":"Journal of the Chemical Society Perkin Transaction (London)"},{"key":"10.1136\/ard.59.11.841_bib19","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1021\/jm9604437","article-title":"Synthesis, structure - activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl]propenamide and related compounds.","volume":"39","author":"Kuo","year":"1996","journal-title":"J Med Chem"},{"key":"10.1136\/ard.59.11.841_bib20","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.1780381111","article-title":"Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study.","volume":"38","author":"Mladenovic","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.11.841_bib21","series-title":"Novel therapeutic agents for the treatment of autoimmune diseases.","first-page":"287","article-title":"Leflunomide: a new immunosuppressive drug.","author":"Scott","year":"1997"},{"key":"10.1136\/ard.59.11.841_bib22","first-page":"1083","article-title":"Prevention of kidney and skin graft rejection in rats by leflunomide a new immunomodulating agent.","volume":"23","author":"Kuchle","year":"1991","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib23","first-page":"763","article-title":"Prolongation of allogeneic transplanted skin grafts and induction of tolerance by leflunomide, a new immunosuppressive isoxazol derivative.","volume":"25","author":"Schorlemmer","year":"1993","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib24","first-page":"745","article-title":"Immunosuppressive effects of leflunomide in a cardiac allograft model.","volume":"25","author":"Williams","year":"1993","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib25","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF01971235","article-title":"Disease modifying activity of HWA 486 on the development of SLE in MRL\/1-mice.","volume":"19","author":"Popovic","year":"1986","journal-title":"Agents Actions"},{"key":"10.1136\/ard.59.11.841_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0192-0561(95)00009-Q","article-title":"Leflunomide prevents the development of experimentally induced myasthenia gravis.","volume":"17","author":"Vidic-Dankovic","year":"1995","journal-title":"Int J Immunopharmacol"},{"key":"10.1136\/ard.59.11.841_bib27","first-page":"381","article-title":"Effects of leflunomide on immune responses and models of inflammation.","volume":"14","author":"Bartlett","year":"1993","journal-title":"Seminars in Immunopathology"},{"key":"10.1136\/ard.59.11.841_bib28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0192-0561(85)90003-7","article-title":"Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity - I. Disease modifying action on adjuvant arthritis of the rat.","volume":"7","author":"Bartlett","year":"1985","journal-title":"Int J Immunopharmacol"},{"key":"10.1136\/ard.59.11.841_bib29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF01966478","article-title":"Disease modifying activity of HWA 486 in rat adjuvant-induced arthritis.","volume":"21","author":"Pasternak","year":"1987","journal-title":"Agents Actions"},{"key":"10.1136\/ard.59.11.841_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/BF01966465","article-title":"Drug actions on delayed-type hypersensitivity in rats with developing and established adjuvant arthritis.","volume":"29","author":"Hambleton","year":"1990","journal-title":"Agents Actions"},{"key":"10.1136\/ard.59.11.841_bib31","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0192-0561(86)90059-7","article-title":"Immunopharmacological profile of HWA 486, a novel isoxazol derivative - II. In vivo immunomodulating effects differ from those of cyclophosphamide, prednisolone, or cyclosporin A.","volume":"8","author":"Bartlett","year":"1986","journal-title":"Int J Immunopharmacol"},{"key":"10.1136\/ard.59.11.841_bib32","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1097\/00007890-199306000-00028","article-title":"Leflunomide, a novel immunosuppresive agent.","volume":"55","author":"Chong","year":"1993","journal-title":"Transplantation"},{"key":"10.1136\/ard.59.11.841_bib33","doi-asserted-by":"crossref","first-page":"12398","DOI":"10.1074\/jbc.270.21.12398","article-title":"Inhibition of protein tyrosine phosphorylation in T cells by a novel immunosuppressive agent, leflunomide.","volume":"270","author":"Xu","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.59.11.841_bib34","first-page":"460","article-title":"The immunosuppressant leflunomide inhibits lymphocyte progression through cell cycle by a novel mechanism.","volume":"272","author":"Cherwinski","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1136\/ard.59.11.841_bib35","first-page":"445","volume":"27","author":"Morris","year":"1995","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4049\/jimmunol.159.1.167","article-title":"In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL\/MpJ-Ipr\/Ipr mice.","volume":"159","author":"Xu","year":"1997","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.11.841_bib37","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00007890-199502150-00013","article-title":"Differential effects of the immunosuppressive agents cyclosporine and leflunomide in vivo.","volume":"59","author":"Lang","year":"1995","journal-title":"Transplantation"},{"key":"10.1136\/ard.59.11.841_bib38","doi-asserted-by":"crossref","first-page":"C279","DOI":"10.1007\/BF01987669","article-title":"Inhibition of interleukin 2 (IL-2)-stimulated tyrosine kinase activity by leflunomide.","volume":"41","author":"Nikcevich","year":"1994","journal-title":"Agents Actions"},{"key":"10.1136\/ard.59.11.841_bib39","first-page":"3079","article-title":"A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-\u00ce\u00b21, and suppression of the immunostimulatory cytokine, IL-2.","volume":"28","author":"Cao","year":"1996","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib40","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/infdis\/163.6.1185","article-title":"New aspects of antimicrobial resistance and the resulting therapeutic dilemmas.","volume":"163","author":"Murray","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1136\/ard.59.11.841_bib41","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.4049\/jimmunol.162.4.2095","article-title":"Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-\u00ce\u00baB activation and gene expression.","volume":"162","author":"Manna","year":"1999","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.11.841_bib42","doi-asserted-by":"crossref","first-page":"29682","DOI":"10.1074\/jbc.270.50.29682","article-title":"Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans.","volume":"270","author":"Fairbanks","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.59.11.841_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1146\/annurev.bi.49.070180.001345","article-title":"Pyrimidine nucleotide biosynthesis in animals: genes, enzymes, and regulation of UMP biosynthesis.","volume":"49","author":"Jones","year":"1980","journal-title":"Annu Rev Biochem"},{"key":"10.1136\/ard.59.11.841_bib44","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0041-1345(96)00523-4","article-title":"In vitro and in vivo effects of leflunomide, brequiner, cyclosporin on pyrimidine biosynthesis.","volume":"29","author":"Silva","year":"1997","journal-title":"Transplant Proc"},{"key":"10.1136\/ard.59.11.841_bib45","series-title":"Biochemistry.","author":"Voet","year":"1990"},{"key":"10.1136\/ard.59.11.841_bib46","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0020-711X(83)90051-4","article-title":"Purine and pyrimidine metabolism in peripheral blood lymphocytes.","volume":"15","author":"Peters","year":"1983","journal-title":"Int J Biochem"},{"key":"10.1136\/ard.59.11.841_bib47","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/0006-2952(95)00255-X","article-title":"Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.","volume":"50","author":"Greene","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1136\/ard.59.11.841_bib48","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/bi952168g","article-title":"The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.","volume":"35","author":"Davis","year":"1996","journal-title":"Biochemistry"},{"key":"10.1136\/ard.59.11.841_bib49","first-page":"3521","article-title":"Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.","volume":"52","author":"Chen","year":"1992","journal-title":"Cancer Res"},{"key":"10.1136\/ard.59.11.841_bib50","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0162-3109(00)00191-0","article-title":"Leflunomide, an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune disease.","volume":"47","author":"Herrmann","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1136\/ard.59.11.841_bib51","first-page":"183","article-title":"Maintaining genetic stability through TP53 mediated checkpoint control.","volume":"29","author":"Wahl","year":"1997","journal-title":"Cancer Surv"},{"key":"10.1136\/ard.59.11.841_bib52","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1101\/gad.10.8.934","article-title":"A reversible, p53-dependent G0\/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage.","volume":"10","author":"Linke","year":"1996","journal-title":"Genes Dev"},{"key":"10.1136\/ard.59.11.841_bib53","first-page":"1171","article-title":"p53 mediates permanent arrest over multiple cell cycles in response to gamma-irradiation.","volume":"57","author":"Linke","year":"1997","journal-title":"Cancer Res"},{"key":"10.1136\/ard.59.11.841_bib54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"p53, guardian of the genome.","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"10.1136\/ard.59.11.841_bib55","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.4049\/jimmunol.149.6.2040","article-title":"IFN-\u00ce\u00b3 and 1,25(OH)2D3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells.","volume":"149","author":"Vey","year":"1992","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.11.841_bib56","first-page":"15","article-title":"Cell surface glycoproteins expressed on activated human T-cells induce production of interleukin-1-beta by monocytic cells: a possible role of CD69.","volume":"4","author":"Isler","year":"1993","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard.59.11.841_bib57","doi-asserted-by":"crossref","first-page":"22027","DOI":"10.1016\/S0021-9258(17)31750-7","article-title":"Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression.","volume":"269","author":"Lacraz","year":"1994","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.59.11.841_bib58","first-page":"571","article-title":"Contact-dependent stimulation of monocytic cells and neutrophils by stimulated human T-cell clones.","volume":"84","author":"Li","year":"1995","journal-title":"J Immunol"},{"key":"10.1136\/ard.59.11.841_bib59","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1002\/eji.1830261021","article-title":"Expression and cleavage of tumor necrosis factor-\u00ce\u00b1 and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells.","volume":"26","author":"Vey","year":"1996","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard.59.11.841_bib60","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/eji.1830270125","article-title":"Human Th 1 cells preferentially induce interleukin (IL)-1\u00ce\u00b2 while Th2 cells induce IL-1 receptor antagonist production upon cell\/cell contact with monocytes.","volume":"27","author":"Chizzolini","year":"1997","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard.59.11.841_bib61","first-page":"663","article-title":"Exposure of T lymphocytes to leflumonide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1\u00ce\u00b2 and metalloproteinases.","volume":"9","author":"Deage","year":"1998","journal-title":"Eur Cytokine Netw"},{"key":"10.1136\/ard.59.11.841_bib62","doi-asserted-by":"crossref","first-page":"21682","DOI":"10.1074\/jbc.273.34.21682","article-title":"Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.","volume":"273","author":"R\u00c3\u00bcckemann","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1136\/ard.59.11.841_bib63","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","article-title":"Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate.","volume":"159","author":"Strand","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1136\/ard.59.11.841_bib64","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(98)09403-3","article-title":"Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial.","volume":"353","author":"Smolen","year":"1999","journal-title":"Lancet"},{"key":"10.1136\/ard.59.11.841_bib65","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/art.1780390503","article-title":"Guidelines for monitoring drug therapy in rheumatoid arthritis.","volume":"39","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.11.841_bib66","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology"},{"key":"10.1136\/ard.59.11.841_bib67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2165\/00063030-199912040-00007","article-title":"How does leflunomide modulate the immune response in rheumatoid arthritis?","volume":"12","author":"Fox","year":"1999","journal-title":"BioDrugs"},{"key":"10.1136\/ard.59.11.841_bib68","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/00007890-199907150-00020","article-title":"In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.","volume":"68","author":"Chong","year":"1999","journal-title":"Transplantation"},{"key":"10.1136\/ard.59.11.841_bib69","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/art.1780330116","article-title":"The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis.","volume":"33","author":"Paulus","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard.59.11.841_bib70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0049-0172(91)90048-5","article-title":"Therapy for rheumatoid arthritis: combinations of disease-modifying drugs and new paradigms of treatment.","volume":"21","author":"Wilke","year":"1991","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.59.11.841_bib71","first-page":"24","article-title":"Approaches to the management of rheumatoid arthritis: rationale for early combination therapy.","volume":"32(suppl 1)","author":"Wilske","year":"1993","journal-title":"Br J Rheumatol"},{"key":"10.1136\/ard.59.11.841_bib72","first-page":"86","article-title":"Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis.","volume":"23","author":"Furst","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1136\/ard.59.11.841_bib73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0049-0172(99)80034-1","article-title":"Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis.","volume":"29","author":"Kremer","year":"1999","journal-title":"Semin Arthritis Rheum"},{"key":"10.1136\/ard.59.11.841_bib74","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/00007890-199457120-00005","article-title":"An evaluation of leflunomide in the canine renal transplantation model.","volume":"57","author":"McChesney","year":"1994","journal-title":"Transplantation"},{"key":"10.1136\/ard.59.11.841_bib75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF02265123","article-title":"Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A.","volume":"45","author":"Thoss","year":"1996","journal-title":"Inflamm Res"},{"key":"10.1136\/ard.59.11.841_bib76","unstructured":"Aventis Pharmaceuticals Inc, (1998) ARAVA prescribing information."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724424576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard.59.11.841","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:38:50Z","timestamp":1737549530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724424576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":76,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["S0003496724424576"],"URL":"https:\/\/doi.org\/10.1136\/ard.59.11.841","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2000,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard.59.11.841","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2000 Copyright 2000 by Annals of the Rheumatic Diseases, Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}